Literature DB >> 32968765

Immune correlates analysis using vaccinees from test negative designs.

Dean A Follmann1, Lori Dodd1.   

Abstract

Determining the effect of vaccine-induced immune response on disease risk is an important goal of vaccinology. Typically, immune correlates analyses are conducted prospectively with immune response measured shortly after vaccination and subsequent disease status regressed on immune response. In outbreaks and rare disease settings, collecting samples from all vaccinees is not feasible. The test negative design is a retrospective design used to measure vaccine efficacy where symptomatic individuals who present at a clinic are assessed for relevant disease (cases) or some other disease (controls) and vaccination status ascertained. This article proposes that test negative vaccinees have immune response to vaccine assessed both for relevant (e.g., Ebola) and irrelevant (e.g., vector) proteins. If the latter immune response is unaffected by active (Ebola) infection, and is correlated with the relevant immune response, it can serve as a proxy for the immune response of interest proximal to infection. We show that logistic regression using imputed immune response as the covariate and case disease as outcome can estimate the prospective immune response slope and detail the assumptions needed for unbiased inference. The method is evaluated by simulation under various scenarios including constant and decaying immune response. A simulated dataset motivated by ring vaccination for an ongoing Ebola outbreak is analyzed. Published by Oxford University Press 2020. This work is written by US Government employees and is in the public domain in the US.

Entities:  

Keywords:  Imputation; Likelihood, Logisitic regression; Regression calibration

Mesh:

Substances:

Year:  2022        PMID: 32968765      PMCID: PMC9216615          DOI: 10.1093/biostatistics/kxaa037

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.279


  16 in total

1.  Nomenclature for immune correlates of protection after vaccination.

Authors:  Stanley A Plotkin; Peter B Gilbert
Journal:  Clin Infect Dis       Date:  2012-03-20       Impact factor: 9.079

2.  A flexible approach to measurement error correction in case-control studies.

Authors:  A Guolo
Journal:  Biometrics       Date:  2008-03-03       Impact factor: 2.571

3.  A framework for assessing immunological correlates of protection in vaccine trials.

Authors:  Li Qin; Peter B Gilbert; Lawrence Corey; M Juliana McElrath; Steven G Self
Journal:  J Infect Dis       Date:  2007-10-02       Impact factor: 5.226

4.  Measurement of Vaccine Direct Effects Under the Test-Negative Design.

Authors:  Joseph A Lewnard; Christine Tedijanto; Benjamin J Cowling; Marc Lipsitch
Journal:  Am J Epidemiol       Date:  2018-12-01       Impact factor: 4.897

5.  Invited Commentary: Beware the Test-Negative Design.

Authors:  Daniel Westreich; Michael G Hudgens
Journal:  Am J Epidemiol       Date:  2016-09-01       Impact factor: 4.897

6.  Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness.

Authors:  Sheena G Sullivan; Eric J Tchetgen Tchetgen; Benjamin J Cowling
Journal:  Am J Epidemiol       Date:  2016-09-01       Impact factor: 4.897

7.  Designing a Study of Correlates of Risk for Ebola Vaccination.

Authors:  M Elizabeth Halloran; Ira M Longini; Peter B Gilbert
Journal:  Am J Epidemiol       Date:  2020-08-01       Impact factor: 4.897

8.  Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

Authors:  Ana Maria Henao-Restrepo; Ira M Longini; Matthias Egger; Natalie E Dean; W John Edmunds; Anton Camacho; Miles W Carroll; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Stefanie Hossmann; Mandy Kader Kondé; Souleymane Kone; Eeva Kuisma; Myron M Levine; Sema Mandal; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; Conall H Watson; Sakoba Kéïta; Marie Paule Kieny; John-Arne Røttingen
Journal:  Lancet       Date:  2015-08-03       Impact factor: 79.321

9.  Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges.

Authors:  Stephen B Kennedy; James D Neaton; H Clifford Lane; Mark W S Kieh; Moses B F Massaquoi; Nancy A Touchette; Martha C Nason; Dean A Follmann; Fatorma K Boley; Melvin P Johnson; Gregg Larson; Francis N Kateh; Tolbert G Nyenswah
Journal:  Clin Trials       Date:  2016-01-14       Impact factor: 2.486

10.  Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in Humans.

Authors:  Joseph H Poetsch; Christine Dahlke; Madeleine E Zinser; Rahel Kasonta; Sebastian Lunemann; Anne Rechtien; My L Ly; Hans C Stubbe; Verena Krähling; Nadine Biedenkopf; Markus Eickmann; Sarah K Fehling; Flaminia Olearo; Thomas Strecker; Piyush Sharma; Karl S Lang; Ansgar W Lohse; Stefan Schmiedel; Stephan Becker; Marylyn M Addo
Journal:  J Infect Dis       Date:  2019-01-29       Impact factor: 5.226

View more
  2 in total

1.  A comparison of the test-negative and the matched case-control study designs for estimation of EV71 vaccine immunological surrogate endpoints from a randomized controlled trial.

Authors:  Li Zhang; Pengfei Jin; Mingwei Wei; Hudachuan Jiang; Jingxin Li; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2022-06-09       Impact factor: 4.526

Review 2.  SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact.

Authors:  Marc Lipsitch; Florian Krammer; Gili Regev-Yochay; Yaniv Lustig; Ran D Balicer
Journal:  Nat Rev Immunol       Date:  2021-12-07       Impact factor: 53.106

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.